Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cytune Pharma currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These cases are distributed among 3 distinct examiners, with BEANE, RANDALL L identified as the busiest examiner holding 1 pending action. This means the 3 pending matters are each assigned to a different individual, spreading the workload across multiple personnel.
The prosecution activity spans 2 distinct art units. Because there are 3 distinct examiners but only 2 distinct art units, there is overlap in the technical groups assigned to this portfolio. Managing these 3 pending office actions requires a strategy that accounts for the nuances of 2 different art units and the individual preferences of 3 different examiners. This structure necessitates a coordinated approach to ensure consistency across the 2 distinct art units involved in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
| CESARE, JOSEPH DAVID | 1 | — | — |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033524 | IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING NON-MELANOMA SKIN CANCER | ABBAS, SYED JARAR | 73d overdue |
| 18683180 | IL-2/IL-15RBETAGAMMA AGONIST COMBINATION WITH ANTIBODY-DRUG CONJUGATES FOR TREATING CANCER | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683180 | IL-2/IL-15RBETAGAMMA AGONIST COMBINATION WITH ANTIBODY-DRUG CONJUGATES FOR TREATING CANCER | BEANE, RANDALL L | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683180 | IL-2/IL-15RBETAGAMMA AGONIST COMBINATION WITH ANTIBODY-DRUG CONJUGATES FOR TREATING CANCER | BEANE, RANDALL L | — | §103§112Other | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18033773 | IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA | CESARE, JOSEPH DAVID | 1675 | §103 | Final Rejection | — | Pending | Apr 25, 2023 |
| 18033524 | IL-2/IL-15R-BETA-GAMMA AGONIST FOR TREATING NON-MELANOMA SKIN CANCER | ABBAS, SYED JARAR | 1674 | §102§112Other | Non-Final OA | 73d overdue | Pending | Apr 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial